Dr. Michael White Promoted to President of Research and Development at IDEAYA Biosciences

IDEAYA Biosciences Elevates Dr. Michael White

In a recent announcement, IDEAYA Biosciences, Inc. has promoted Dr. Michael White from his position as Chief Scientific Officer to the President of Research and Development. This strategic move, effective September 28, 2026, reflects the company's commitment to enhancing its oncology capabilities.

Yujiro S. Hata, President and CEO of IDEAYA Biosciences, expressed his enthusiasm for Dr. White's promotion, highlighting his exceptional leadership over the past five years. Dr. White has been instrumental in driving IDEAYA's mission to develop targeted therapeutics aimed at addressing significant unmet medical needs in oncology. Under his guidance, the company is poised to continue the development of its industry-leading precision medicine oncology pipeline. This pipeline targets a variety of solid tumor indications, notably uveal melanoma, pancreatic cancer, and several forms of lung and colorectal cancers.

Dr. White's journey with IDEAYA began in 2021 when he took on the role of Chief Scientific Officer. His background is distinguished by a robust career in both industry and academia, including a significant role at Pfizer, where he oversaw the Tumor Biology division and contributed to the development of first-in-class oncology therapies. Prior to his tenure at Pfizer, Dr. White built an impressive academic career at UT Southwestern, serving as a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program.

Among his accolades, Dr. White was honored in 2015 with the inaugural Outstanding Investigator's Award from the National Cancer Institute (NCI). With over 150 publications and more than 30,000 citations, he is regarded as a leading figure in his field. Dr. White earned his Ph.D. in Biology from the University of North Carolina at Chapel Hill, followed by postdoctoral research at Cold Spring Harbor Laboratories.

Upon accepting his new role, Dr. White stated, "I am honored to take on this expanded role at such a pivotal time for IDEAYA. We have achieved remarkable progress in translating our precision medicine capabilities into a comprehensive oncology portfolio. Our late-stage programs hold the potential to establish new standards of care, while our early-stage efforts may introduce groundbreaking therapeutic options."

IDEAYA Biosciences stands out in the field of precision medicine. The company focuses on the discovery, development, and commercialization of innovative cancer therapies through an integrated approach that combines small-molecule drug discovery and translational biomarker validation. With a deep pipeline targeting molecularly defined solid tumors, IDEAYA's mission is to deliver personalized oncology treatments that aim to improve clinical outcomes and alter the course of cancer.

Dr. White's leadership is expected to propel IDEAYA's initiatives forward, particularly in developing innovative small molecules and antibody-drug conjugates designed for molecularly defined cancers. As he embarks on this new chapter, the entire oncology community is watching closely, hopeful for advancements in cancer treatments that significantly extend and enhance patients' lives.

In conclusion, IDEAYA's commitment to R&D excellence, exemplified by Dr. White's leadership, underscores the company's goal to bring forth the next wave of precision oncology therapies that are not only effective but deeply personalized. The industry eagerly anticipates the advancements that will result from this promotional appointment.